PARTNERSHIPS
Partner with us
We are committed to developing best-in-class therapeutics for immunological and inflammatory diseases and welcome the opportunity to explore collaborations with potential partners around the world.
Partners
Inmagene and Hutchison China MediTech Limited (“HUTCHMED”) (NASDAQ/AIM: HCM) have formed a strategic partnership to develop MAG-007 to treat a range of immunologic and inflammatory diseases. Led and funded by Inmagene, both products are in global clinical development.
To expedite the development of MAG-018, an in-house discovered asset via our proprietary QuadraTek® platform, Inmagene has partnered with Aditum Bio to establish Celexor Bio, a new biotech company. Celexor has licensed exclusive global rights to develop, manufacture, and commercialize MAG-018 from Inmagene.
To explore partnership opportunities, please contact our business development team by emailing bdpartner@miragene.com.